VCNX — Vaccinex, Inc.
$1.00
+$0.00 (+0.00%)
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.
Market Cap
$2.68M
Forward P/E
-7.1x
52-Week Range
N/A
VCNX Price History
Revenue vs. Net Income
$625K
Revenue · FY2020
Annual. Net margin is shown under each year.
Free Cash Flow
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
